Correlation Between NovaBay Pharmaceuticals and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both NovaBay Pharmaceuticals and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NovaBay Pharmaceuticals and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NovaBay Pharmaceuticals and Immix Biopharma, you can compare the effects of market volatilities on NovaBay Pharmaceuticals and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NovaBay Pharmaceuticals with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of NovaBay Pharmaceuticals and Immix Biopharma.

Diversification Opportunities for NovaBay Pharmaceuticals and Immix Biopharma

-0.22

Correlation Coefficient

NovaBay Pharmaceuticals  Immix Biopharma

Very good diversification

The 3 months correlation between NovaBay and Immix is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding NovaBay Pharmaceuticals and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and NovaBay Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NovaBay Pharmaceuticals are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of NovaBay Pharmaceuticals i.e., NovaBay Pharmaceuticals and Immix Biopharma go up and down completely randomly.

Pair Corralation between NovaBay Pharmaceuticals and Immix Biopharma

Considering the 90-day investment horizon NovaBay Pharmaceuticals is expected to generate 0.83 times more return on investment than Immix Biopharma. However, NovaBay Pharmaceuticals is 1.21 times less risky than Immix Biopharma. It trades about -0.2 of its potential returns per unit of risk. Immix Biopharma is currently generating about -0.24 per unit of risk. If you would invest  68.00  in NovaBay Pharmaceuticals on December 10, 2024 and sell it today you would lose (10.00) from holding NovaBay Pharmaceuticals or give up 14.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

NovaBay Pharmaceuticals  vs.  Immix Biopharma

NovaBay Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in NovaBay Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal fundamental drivers, NovaBay Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Immix Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immix Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with NovaBay Pharmaceuticals and Immix Biopharma

The main advantage of trading using opposite NovaBay Pharmaceuticals and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NovaBay Pharmaceuticals position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind NovaBay Pharmaceuticals and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.